drugset
Drugs / SAL0140
last change Jun 2026 re-read 3 minutes ago

SAL0140

Developed for
hypertensive disorder · chronic kidney disease · primary aldosteronism
Investigated by
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Trials 4

today NCT07647133 · Ph 2 NCT07646535 · Ph 2 NCT07654140 · Ph 2 NCT07051603 · Ph 1
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07051603 Jun 2025 → Jan 2026 overdue hypertensive disorder Shenzhen Salubris Pharmaceuticals Co., Ltd. Recruiting No outcome recorded
Phase 23 trials
Phase 2 NCT07647133 Jun 2026 → Oct 2027 expected chronic kidney disease Shenzhen Salubris Pharmaceuticals Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT07646535 Jun 2026 → Apr 2027 expected primary aldosteronism Shenzhen Salubris Pharmaceuticals Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT07654140 Dec 2025 → Mar 2027 expected hypertensive disorder Shenzhen Salubris Pharmaceuticals Co., Ltd. Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2025-09-29 Shenzhen Salubris Pharmaceuticals Co., Ltd. Regulatory 最新！信立泰SAL0140新适应症临床试验申请获受理，高血压治疗或迎新突破 salubris.com ↗
2025-04-28 Shenzhen Salubris Pharmaceuticals Co., Ltd. Regulatory 信立泰高血压新药SAL0140临床试验获批 salubris.com ↗
近日，信立泰收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物 SAL0140片（项目代码：SAL0140）开展治疗未控制高血压的临床试验。
2025-02-14 Shenzhen Salubris Pharmaceuticals Co., Ltd. Regulatory 信立泰SAL0140临床试验申请获受理，高血压治疗或迎新突破 salubris.com ↗
近日，信立泰宣布，其自主研发的创新小分子药物SAL0140片（项目代码：SAL0140）临床试验申请已获国家药品监督管理局（NMPA）正式受理。

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as SAL0140 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07654140 ↗
3

NCT07051603 ↗

NCT07646535 ↗

NCT07647133 ↗
Route Oral “administered as a single or multiple oral dose” NCT07051603 ↗